As a result, the biotherapeutics firm will gain further access and rights to certain platform and manufacturing technologies, as well as an exclusive license to a clinical-stage mesothelin chimeric antigen receptor (CAR) T-cell therapy product developed at the university's Center for Cellular Immunotherapies. In addition, Tmunity said it has committed to further fund T-cell engineering research programs at Penn. The company will receive exclusive rights to products and technologies developed by those programs, subject to certain limitations.

What's more, Tmunity will retain certain rights to intellectual property originating from the laboratories of its scientific founders at Penn, including Dr. Carl June, Bruce Levine, PhD, and James Riley, PhD. The company has already licensed four clinical-stage solid tumor CAR T programs created at the university.

Thermo Fisher inks CAR T deal with JW Therapeutics
Thermo Fisher has signed a marketing agreement with Chinese firm JW Therapeutics to supply that company with its Gibco CTS Dynabeads CD3/CD28. The agreement...

Artiva, Merck to develop CAR NK cell therapies
Artiva Biotherapeutics and Merck have signed an agreement to develop chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics for solid tumors.

Precision BioSciences nabs patent for CAR construct tech
Precision BioSciences has received a notice of allowance from the U.S. Patent and Trademark Office for patent application, No. 16/908, 030. The patent...

Dual-antigen CAR T system could be effective at treating solid tumors in children
A new chimeric antigen receptor (CAR) T-cell system that targets two tumor antigens may be effective at treating difficult solid tumors in children in...

Kuur provides positive interim clinical data for CAR-NKT cell therapy programs
Kuur Therapeutics has released results from phase I clinical trials evaluating its off-the-shelf chimeric antigen receptor natural killer T (CAR-NKT)-cell...